Gender differences among patients with Hepatitis C virus undergoing rehabilitation through methadone maintenance treatment by Massah, O et al.
55
I ranian R ehabilitation Journal March 2018, Volume 16, Number 1
Research Paper: Gender Differences Among Patients With 
Hepatitis C Virus Undergoing Rehabilitation Through 
Methadone Maintenance Treatment
Omid Massah1, Enayatollah Bakhshi2* , Sara Shishehgar3, Afsaneh Moradi4
1. Substance Abuse and Dependence Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
2. Department of Biostatistics, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
3. Department of Public Health, Faculty of Health, University of Technology Sydney, Sydney, Australia.
4. Department of Educational Psychology, Faculty of Educational Sciences and Psychology, Alzahra University, Tehran, Iran. 
* Corresponding Author: 
Enayatollah Bakhshi, PhD
Address: Department of Biostatistics, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran. 
Tel: +98 (21) 22180086
E-mail: bakhshi@razi.tums.ac.ir
Objectives: Hepatitis C Virus (HCV) is a health problem among patients undergoing 
rehabilitation through methadone maintenance treatment in Iran, the most populous Persian 
Gulf country. The study aimed to examine gender differences among a group of methadone 
maintenance treatment patients with HCV problem.
Methods: Overall 150 patients (n=75 men, n=75 women) were enrolled from nine methadone 
clinics in Tehran. The study was conducted between July 2013 and June 2014. Participants of 
the two genders were compared in baseline characteristics, perceived stress, social support, 
coping strategies and mental health.
Results: Men were more likely to report being currently on parole than women (χ²(1)=9.23). Age 
of first illicit drug use was significantly higher among men than women (t(121)=2.43). Men were 
more likely to report drug injection in the last 12 months compared with women (χ²(1)=4.62). 
Men were more likely to report criminal charges (t(121)=2.21) and being in correctional facilities 
(χ²(1)=5.32) compared with women. Women reported higher levels of emotion-focused coping 
than men. Despite women reporting more social support [4.20(0.79)], they also reported higher 
levels of emotion-focused coping [2.66(0.55)] than men. Women were more likely to have a 
current mental health disorder (χ²(1)=8.15) than men.
Discussion: The study results demonstrated some gender differences in baseline characteristics 
and psychological problems. Such differences may have important impacts on methadone 
treatment outcomes. Further studies are suggested.
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1. Introduction
epatitis C Virus (HCV) is a serious cause 
of chronic liver diseases, as well as the 
most common chronic blood borne in-
fection in the world [1]. Overall, 170 
million men and women are infected 
with HCV [2, 3]. About 70-80% of in-
fected patients develop chronic infections, which lead to 
serious health problems [2-4]. Hepatitis C is very com-
mon in intravenous drug users in Iran [5, 6] and HCV is a 
serious health concern among methadone patients in Iran 
[7]. A study of 539 injection opiate users in methadone 
treatment indicated that all of them were HCV-infected. 
There was a significant relationship between the rate of 
HCV prevalence and sharing needles [8]. A study was 
conducted on 259 methadone patients. The HCV preva-
lence was 50%. The study indicated that the rate of un-
safe drug injection and high risk sexual behaviors were 
lower among the participants after receiving the treat-
ment. Furthermore, methadone treatment was an effec-
tive intervention to reduce HCV transmission [7].
Multiple reasons can increase HCV in methadone 
treatment. Some methadone patients are already in-
fected with HCV at the time that they enter drug treat-
ment. For others, the high prevalence of HCV ensures 
that even occasional risky drug use can lead to HCV. 
Other factors contributing to the HCV prevalence in-
clude an inadequate methadone dose [9]. Psychologi-
cal problems have been frequently reported among 
methadone patients with HCV problem. A study of 
methadone patients indicated that depression, anxiety, 
fatigue and irritability were associated with the HCV 
prevalence. Patients with drug dependence had a high 
chance to discontinue HCV-treatment early in the first 
three treatment months [10]. A study of 3755 metha-
done patients with HCV problem indicated that 14% 
had received HCV treatment during the study period. 
Annual HCV treatment rates during methadone treat-
ment ranged between 1.3% in 2005 and 2.6% in 2008 
with no significant changes over time. HCV treatment 
uptake was associated with heavy benzodiazepine use 
for poor mental health [11]. This indicates an increased 
awareness for HCV and associated psychological 
problems among methadone patients [12].
To date, there are few studies about HCV problem 
among men and women in methadone treatment. The 
current study aimed to examine gender differences 
among a group of methadone patients with HCV prob-
lem. This was conducted in four domains: baseline char-
acteristics, perceived stress, social support, coping strat-
egies and mental health.
2. Methods
Study design and settings
A cross-sectional and multicenter study was designed. 
Nine methadone clinics in Tehran, Iran were the study 
sites. Overall, seven study sites were in middle socio-
economic areas. Two of the study sites were women-on-
ly centers in low-socio-economic areas. The study was 
part of a larger study which was approved by University 
of Social Welfare and Rehabilitation Sciences. 
Participants
Overall, 150 participants were randomly recruited. 
Overall, 15 or 16 male and female participants were 
recruited from each center. Following criteria were 
needed for recruitment: (1) reporting at least 18 years 
old; (2) being able to complete the study question-
naires; and (3) providing serological specimens for 
HCV. Furthermore, eligible candidates were needed to 
be in methadone treatment for at least one month. Par-
ticipants were excluded if they reported severe drug 
withdrawal and/or intoxication symptoms at the time 
of interviewing. Fortunately, no participant was ex-
cluded from this study.
Questionnaires
Baseline Checklist (BC)
A checklist was designed to collect baseline characteris-
tics and drug use details as well as current mental health 
status. The assessed reliability of the checklist in two 
weeks was (a=92) in this study. 
Perceived Stress Scale (PSS)
The Persian version of the PSS was administered to 
collect data on stress. The PSS is a 10-item measure of 
perceived stress. The questionnaire has high reliability 
and validity [13]. The assessed reliability of the PSS in 
two weeks was (a=90) in this study.
Brief Cope Scale (BCS)
The Persian version of the BCS was administered to 
collect data on coping strategies. The BCS is a 28-item 
self-report measure of adaptive and maladaptive coping 
skills [14]. The assessed reliability of the BCS in two 
weeks was (a=91) in this study.
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Social Support Survey (SSS)
The Persian version of the SSS was administered to 
collect data on social support. The questionnaire is 
a 13-item self-report measure of social support. The 
measure has four subscales-emotional/informational, 
tangible, affectionate, and positive social interaction-
as well as an overall social support index [15]. The 
assessed reliability of the questionnaire in two weeks 
was (a=88) in this study.
Data analyses
Individual and demographic variables were examined 
by gender. Independent t-tests and Chi-square (χ²) tests 
were performed to analyze the data. All analyses were 
conducted using SPSS version 22 and statistical signifi-
cance was set at P<0.05.
Study procedure
A total of 150 participants met the inclusion criteria 
and signed informed consent to enrol in the study. The 
study was conducted in a private interview room at each 
study site between July 2013 and June 2014. Participa-
tion was voluntary and confidential. Consent form was 
obtained from each participant. All participants had one 
hour interviews with two trained clinical psychologists 
to complete the questionnaires.
3. Results
Demographics
Participants were in the age range of 32-52 years. 
Demographic characteristics for men and women are 
presented in Table 1. Men were more likely to report 
being currently on parole than women (χ²(1)=9.23). Age 
of first illicit drug use was significantly lower among 
women than men (t(121)=2.43). Men were more likely 
to report drug injection in the last 12 months compared 
with women (χ²(1)=4.62). Men were more likely to re-
port criminal charges (t(121)=2.21) and being in correc-
tional facilities (χ²(1)=5.32) compared with women.
Psychological problems
There were no gender differences in perceived 
stress. Despite women reporting more social support 
[4.20(0.79)], they also reported higher levels of emo-
tion-focused coping [2.66(0.55)] than men. There was 
no effect of gender in problem-focused coping. Women 
were more likely to have a current mental health disorder 
(χ²(1)=8.15) (Table 2).
4. Discussion
Little research has examined gender differences among 
HCV-infected patients in methadone treatment. The 
present findings suggest that there were some differenc-
es among the baseline characteristics of the participants. 
Higher rates of current parole, drug injection, criminal 
charges and being in correctional facilities among men 
were considerable compared with women. In contrast, 
women reported lower ages of initial illicit drug use than 
men. Such characteristics were likely to contribute to en-
gagement in high risk behaviors and the emergence of 
HCV prevalence among the participants. Furthermore, 
such characteristics may reduce positive treatment out-
comes among the participants. This is consistent with 
previous studies which indicate that drug-dependent 
men with HCV problem have higher rates of criminal-
ity, drug injection, high risk behaviors and imprisonment 
[16-19]. Further studies are suggested.
The study findings indicated that there were no gender 
differences in perceived stress. Despite women reporting 
more social support, they also reported higher levels of 
emotion-focused coping than men. Furthermore, women 
were more likely to have a current mental health disor-
der. The reported psychological problems among these 
women may increase HCV problem. When considering 
treatment for HCV, particular attention must be paid to 
mental health conditions.
These study findings are consistent with some studies 
in other countries. A study of 111 patients showed high 
lifetime (82%) and current (57%) diagnosis rates of sub-
stance use disorders. Lifetime prevalence of any mood 
disorder was 67% while current prevalence of any mood 
disorder was 35%. Lifetime prevalence of any anxiety 
disorder was 63% while current prevalence of any mood 
disorder was 22%. A total of 66% of the patients re-
ceived psychiatric medications prior to HCV treatment; 
more than half were receiving antidepressant medica-
tions. Overall, 15% of the patients were ineligible for 
HCV treatment due to psychiatric severity [20]. A study 
of Thai methadone clients indicated that depression was 
prevalent among HCV-infected patients. Positive HCV 
status and greater perceived stress were independently 
associated with depression [21]. A study of 576 metha-
done participants; 514 were HCV positive indicated 
high levels of anxiety (21.0%), depression (27.2%), at-
tempted suicide (32.7%), and taking psychiatric medi-
cations (16.1%) [22]. The prevalence of psychological 
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Table 1. Baseline characteristics by gender 
Characteristics Men (n=75) Women (n=75) t/χ² P
Age range 34-51 32-52 - -
Marriage 
n (%)
Married 38(50.7) 36(48.0) χ²(2)=3.01 0.23
Divorced/separated 22(29.3) 22(29.3)
Never married 15(20.0) 17(22.7)
Socio-economic status 
n (%)




<6 years 40(53.3) 33(44.0) χ²(2)=5.42 0.62
6-10 years 35(46.7) 42(56.0)
Employment 
n (%)
Employed 42(56.0) 41(54.7) χ²(2)=4.62 0.18
Jobless 33(44.0) 34(45.3)
Currently on parole 
n (%)
Yes 23(30.7) 6(8.0) χ²(1)=9.23* 0.01
No 52(69.3) 69(92.0)
Age of first drug use¹   21.2(10.0) 17.3(8.2) t(121)=2.43*
Drug injection 
n (%)²
Yes 18(24.0) 4(5.3) χ²(1)=4.62*
No 57(76.0) 71(94.7)
Total criminal charges 11.8(10.7) 7.8(8.2) t(121)=2.21* 0.05
Age of HCV3 35(8.4) 36(9.2) t(121)=1.31
HCV in prison4 7.8(3.2) 7.6(3.1) t(119)=0.01 0.98
In correctional facility 18(24.0) 4(0.05) χ²(1)=5.32* 0.01
 * P<0.05; ¹ Mean(SD); ² Drug injection in the last 12 months; 3 Age of first diagnosis of HCV; 4 Number of HCV risk behaviors
Table 2. Psychological problems by gender 
Variable Men (n=75) Women (n=75) t/χ²
Perceived stress¹ 18.20(8.0) 18.70(6.5)
Social support¹ 3.65(0.81) 4.20(0.79)*
Coping¹
Emotion-focused coping 2.42(0.47) 2.66(0.55)*
Problem-focused coping 3.15(0.65) 3.20(0.63)
Current health 
n (%)²
No 18(24.0) 38(50.7) χ²(1)=8.15*
Yes 57(76.0) 37(49.3)
¹ Mean(SD); ² Mental health or psychiatric disorders
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problems among this group demands a timely treatment 
[23]. There are many barriers to the treatment of HCV in 
addict patients in Iran [24] and their gender differences 
should be considered for therapeutic planning.
The current study had several limitations. First, the 
study was cross-sectional. Second, the study was limited 
to Tehran. Therefore, the study results may not be gen-
eralizable all HCV-infected methadone patients or other 
parts of Iran. Further studies with more male and female 
participants in other parts of Iran are suggested.
5. Conclusion
The study results indicated some gender differences 
in baseline characteristics and psychological problems 
among HCV-infected men and women. Such differences 
may have crucial impacts on methadone treatment out-
comes. In summary, HCV is one of many challenges 
which must be met in the process of providing metha-
done treatment for opioid-dependent patients. Further 
research in gender differences, epidemiology and HCV 
treatment is essential if better methadone outcomes are 
to be achieved.
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